MUC1 and MUC5AC implication in Tunisian colorectal cancer patients
Adenocarcinoma
/ metabolism
Biomarkers, Tumor
/ metabolism
Colectomy
/ methods
Colorectal Neoplasms
/ metabolism
Female
Gene Expression Profiling
/ methods
Humans
Immunohistochemistry
Intestinal Mucosa
/ metabolism
Kaplan-Meier Estimate
Lymphatic Metastasis
/ pathology
Male
Middle Aged
Mucin 5AC
/ metabolism
Mucin-1
/ metabolism
Neoplasm Staging
Prognosis
Tunisia
/ epidemiology
Colorectal cancer
MUC1
MUC5AC
immunohistochemistry
RT-PCR
Journal
Turkish journal of medical sciences
ISSN: 1303-6165
Titre abrégé: Turk J Med Sci
Pays: Turkey
ID NLM: 9441758
Informations de publication
Date de publication:
26 02 2021
26 02 2021
Historique:
received:
04
03
2020
accepted:
24
09
2020
entrez:
24
9
2020
pubmed:
25
9
2020
medline:
3
11
2021
Statut:
epublish
Résumé
Mucins, such as MUC1 and MUC5AC, are known for their protective and moisturizing role in intestinal epithelium. Their expression is tightly controlled given their essential role in normal tissue homeostasis, whereas their deregulation leads to chronic inflammation, and even cancer. This study aimed to assess the expression profiles of MUC1 and MUC5AC and their implications in colorectal carcinogenesis. A retrospective study of 202 patients who underwent colorectal cancer (CRC) surgery was conducted. The expression of MUC1 and MUC5AC was investigated by immunohistochemistry and reverse-transcription polymerase chain reaction (RT-PCR). Statistical analysis of mucin expression pattern, as well as the clinicopathological criteria of the patients, was performed using the chi-square test, survival curves were plotted using the Kaplan—Meier product-limit method, and differences between the survival curves were tested using the log-rank test. The expression of both mucins was abnormally high in the tumor tissues for both mRNA and protein. MUC1 expression was correlated with advanced cancer stages and lymph node metastases for both the mRNA (P < 0.016 and P < 0.002, respectively) and protein level (P < 0.006 and P < 0.001, respectively). However, MUC5AC expression did not pinpoint any significant association between the clinicopathological criteria, but patients who expressed MUC5AC showed an increase in overall survival (P < 0.009). The expression of MUC1 might be a poor prognostic biomarker in CRC and could play a role in tumor transformation and metastasis. However, MUC5AC expression might be a good prognostic in the Tunisian cohort.
Sections du résumé
Background/aim
Mucins, such as MUC1 and MUC5AC, are known for their protective and moisturizing role in intestinal epithelium. Their expression is tightly controlled given their essential role in normal tissue homeostasis, whereas their deregulation leads to chronic inflammation, and even cancer. This study aimed to assess the expression profiles of MUC1 and MUC5AC and their implications in colorectal carcinogenesis.
Materials and methods
A retrospective study of 202 patients who underwent colorectal cancer (CRC) surgery was conducted. The expression of MUC1 and MUC5AC was investigated by immunohistochemistry and reverse-transcription polymerase chain reaction (RT-PCR). Statistical analysis of mucin expression pattern, as well as the clinicopathological criteria of the patients, was performed using the chi-square test, survival curves were plotted using the Kaplan—Meier product-limit method, and differences between the survival curves were tested using the log-rank test.
Results
The expression of both mucins was abnormally high in the tumor tissues for both mRNA and protein. MUC1 expression was correlated with advanced cancer stages and lymph node metastases for both the mRNA (P < 0.016 and P < 0.002, respectively) and protein level (P < 0.006 and P < 0.001, respectively). However, MUC5AC expression did not pinpoint any significant association between the clinicopathological criteria, but patients who expressed MUC5AC showed an increase in overall survival (P < 0.009).
Conclusion
The expression of MUC1 might be a poor prognostic biomarker in CRC and could play a role in tumor transformation and metastasis. However, MUC5AC expression might be a good prognostic in the Tunisian cohort.
Identifiants
pubmed: 32967412
doi: 10.3906/sag-2003-29
pmc: PMC7991860
doi:
Substances chimiques
Biomarkers, Tumor
0
MUC1 protein, human
0
MUC5AC protein, human
0
Mucin 5AC
0
Mucin-1
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
309-318Informations de copyright
This work is licensed under a Creative Commons Attribution 4.0 International License.
Déclaration de conflit d'intérêts
The authors declare that there are no conflicts of interest.
Références
Clin Exp Pharmacol Physiol. 2017 Nov;44(11):1099-1105
pubmed: 28762513
World J Gastroenterol. 2018 Sep 28;24(36):4164-4177
pubmed: 30271081
Carcinogenesis. 2018 May 3;39(5):633-651
pubmed: 29415129
Mod Pathol. 2013 Dec;26(12):1642-56
pubmed: 23807779
World J Gastroenterol. 2010 Aug 28;16(32):4089-94
pubmed: 20731025
Mol Cancer. 2020 Feb 25;19(1):37
pubmed: 32098629
Am J Gastroenterol. 2017 Jan;112(1):172-183
pubmed: 27845339
Pediatr Dev Pathol. 2010 Jan-Feb;13(1):24-31
pubmed: 19025220
Medicine (Baltimore). 2015 Dec;94(50):e2286
pubmed: 26683959
PLoS One. 2015 Sep 14;10(9):e0138049
pubmed: 26367866
Cancer Lett. 2016 May 1;374(2):304-14
pubmed: 26898938
Ann Diagn Pathol. 2013 Apr;17(2):226-9
pubmed: 22405522
Indian J Gastroenterol. 2015 Jan;34(1):63-7
pubmed: 25731647
Int J Clin Exp Pathol. 2013;6(4):613-21
pubmed: 23573307
Virchows Arch. 2014 Oct;465(4):395-400
pubmed: 25108707
Cancer Sci. 2013 Jul;104(7):958-64
pubmed: 23566254
BMC Genomics. 2017 Apr 24;18(1):322
pubmed: 28438116
J Clin Diagn Res. 2017 Apr;11(4):EC30-EC34
pubmed: 28571146
Cancer Causes Control. 2010 Feb;21(2):313-21
pubmed: 19924550
Gastroenterol Res Pract. 2019 Dec 20;2019:2391670
pubmed: 31933627
Cancer Metastasis Rev. 2019 Jun;38(1-2):237-257
pubmed: 30680581
Oncol Lett. 2017 Jul;14(1):1011-1016
pubmed: 28693267
CA Cancer J Clin. 2017 May 6;67(3):177-193
pubmed: 28248415
Virchows Arch. 2016 Sep;469(3):255-65
pubmed: 27298226
Pancreas. 2016 Sep;45(8):1131-5
pubmed: 26967453
Oncogene. 2016 Aug 4;35(31):4112-21
pubmed: 26751774
J Clin Gastroenterol. 2019 Jul;53(6):434-440
pubmed: 29782466
Int J Clin Exp Pathol. 2019 May 01;12(5):1731-1737
pubmed: 31933991
Rev Esp Patol. 2018 Oct - Dec;51(4):204-209
pubmed: 30269770
Cancer Biother Radiopharm. 2016 Sep;31(7):261-7
pubmed: 27610469
Eur J Cancer. 2009 Jan;45(1):33-47
pubmed: 18938071
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Cancers (Basel). 2015 Feb 10;7(1):342-52
pubmed: 25675408